255. Deputy Ken O'Flynn asked the Minister for Health whether any analysis has been conducted on the effectiveness of Publicjobs compared with international journal advertising in generating consultant appointments. [40607/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions asked by Ken O'Flynn .
3,835 questions match, newest first.
256. Deputy Ken O'Flynn asked the Minister for Health the number of consultant recruitment campaigns in 2025 which fail. [40608/26]
257. Deputy Ken O'Flynn asked the Minister for Health the total annual expenditure under the treatment abroad scheme in each year since 2020; the number of approved patients in each year; and the average approved expenditure per patient annually. [40614/26]
258. Deputy Ken O'Flynn asked the Minister for Health whether expenditure and activity data reviewed during quarterly treatment abroad scheme oversight meetings with the Department of Health is recorded in a standardised reporting format; and if she will provide copies of the reporting templates used. [40615/26]
259. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme records activity data by clinical speciality, treatment category, age cohort or referral pathway; and if she will provide a breakdown of the categories currently recorded. [40616/26]
260. Deputy Ken O'Flynn asked the Minister for Health the dates on which the treatment abroad scheme was audited by the HSE Internal Audit function or the Comptroller and Auditor General since 2020; the scope of each audit; and whether any recommendations or governance concerns were identified. [40617/26]
261. Deputy Ken O'Flynn asked the Minister for Health whether any internal reports, dashboards, expenditure summaries or performance-monitoring documents relating to the treatment abroad scheme are routinely furnished to the Department of Health; and if she will provide details of the documents concerned. [40618/26]
262. Deputy Ken O'Flynn asked the Minister for Health whether the treatment abroad scheme maintains separate expenditure or activity reporting for referrals involving minors. [40619/26]
263. Deputy Ken O'Flynn asked the Minister for Health the number of treatment abroad scheme applications submitted, approved, refused and withdrawn in each HSE health region in each year since 2020. [40620/26]
264. Deputy Ken O'Flynn asked the Minister for Health whether any internal analysis has been conducted comparing treatment abroad scheme referral rates per capita across HSE health regions. [40621/26]
265. Deputy Ken O'Flynn asked the Minister for Health whether any equality impact assessment or access equity review has been conducted in relation to regional variation in treatment abroad scheme utilisation. [40622/26]
266. Deputy Ken O'Flynn asked the Minister for Health the dates and titles of all Internal Audit Office or Comptroller and Auditor General audits relating to the treatment abroad scheme since 2020. [40623/26]
267. Deputy Ken O'Flynn asked the Minister for Health whether any approval-rate benchmarking exists between specialties, consultants or regions under the treatment abroad scheme. [40624/26]
268. Deputy Ken O'Flynn asked the Minister for Health which officer or division holds responsibility for monitoring consistency of treatment abroad scheme decision-making nationally. [40625/26]
1111. Deputy Ken O'Flynn asked the Minister for Health whether her Department or the HSE has carried out any national assessment since 2020 of the annual cost to the Exchequer of unused, expired, uncollected, or otherwise wasted medicines under State-funded medicine schemes; and if she will publish any such assessment. [38763/26]
1112. Deputy Ken O'Flynn asked the Minister for Health whether the HSE records the quantity and estimated value of unused or expired medicines returned to community pharmacies under State-funded medicine schemes; and if not, whether she intends to establish such a reporting mechanism. [38764/26]
1113. Deputy Ken O'Flynn asked the Minister for Health what policy measures are currently in place to reduce avoidable medicines waste under the GMS, DPS, LTI and other community drug schemes. [38765/26]
1114. Deputy Ken O'Flynn asked the Minister for Health whether his Department has examined the role of repeat prescribing, automatic renewals, phased dispensing, blister-pack changes, and non-adherence in contributing to medicines waste; and whether any reform proposals are under consideration. [38766/26]
1115. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has a national medicines waste reduction strategy; and if not, whether one will be developed in light of recent research estimating annual medicines waste at over €37.5 million. [38767/26]
1116. Deputy Ken O'Flynn asked the Minister for Health whether the HSE has estimated the environmental impact of unused or expired medicines, including disposal, incineration, contamination risk, and pharmaceutical residues entering water systems. [38768/26]
1117. Deputy Ken O'Flynn asked the Minister for Health when the proposed national scheme for safe disposal of unused medicines will be introduced; what funding has been allocated; whether it will involve community pharmacies; and whether it will operate nationally. [38769/26]
1118. Deputy Ken O'Flynn asked the Minister for Health whether the HSE reimburses medicines which are dispensed but never collected by patients; what safeguards exist to prevent unnecessary reimbursement; and whether data on uncollected medicines is centrally collected. [38770/26]
1119. Deputy Ken O'Flynn asked the Minister for Health whether medication reviews for patients on multiple prescriptions are being used systematically to reduce over-prescribing, duplication, and avoidable waste; and what targets or KPIs apply. [38771/26]
1120. Deputy Ken O'Flynn asked the Minister for Health whether his Department has assessed potential savings from reducing medicines waste by 10%, 20% or 30%; and whether such savings have been modelled for reinvestment in frontline pharmacy or prescribing services. [38772/26]
1128. Deputy Ken O'Flynn asked the Minister for Health whether any HSE national policy, clinical guideline, serious incident framework, or safety protocol explicitly references signs of life following termination of pregnancy. [38839/26]